SEC Company Response from ORAMED PHARMACEUTICALS INC. (ORMP) (CIK 0001176309) (ORMP) — Feb 6, 2020

ORAMED PHARMACEUTICALS INC. (ORMP) (CIK 0001176309)
Date: Feb. 6, 2020 · CIK: 0001176309 · Accession: 0001213900-20-002759

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-236194

Date

February 6, 2020

Author

Not clearly detected

Form

CORRESP

Company

ORAMED PHARMACEUTICALS INC. (ORMP) (CIK 0001176309)

Letter

VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission Washington, D.C. 20549 Registration Statement on Form S-3 File No. 333-236194

Re: Oramed Pharmaceuticals Inc.

Dear Sir or Madam:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Oramed Pharmaceuticals Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced registration statement be accelerated so that it will be declared effective at 2:00 p.m., Eastern Time, on February 10, 2020, or as soon as practicable thereafter.

The Registrant respectfully requests that it be notified of such effectiveness by a telephone call to Howard E. Berkenblit of Zysman, Aharoni, Gayer and Sullivan & Worcester LLP at (617) 338-2979 and that such effectiveness also be confirmed in writing.

Very truly yours,
Oramed Pharmaceuticals Inc.

Show Raw Text

CORRESP
1
filename1.htm

February 6, 2020

VIA EDGAR

Chris Edwards

Division of Corporation Finance

United States Securities and Exchange Commission

100 F Street, NE

Washington, D.C. 20549

    Re:
    Oramed Pharmaceuticals Inc.

    Registration Statement on Form S-3

    File No. 333-236194

Dear Sir or Madam:

Pursuant to Rule 461
under the Securities Act of 1933, as amended, Oramed Pharmaceuticals Inc. (the “Registrant”) hereby requests that the
effective date of the above-referenced registration statement be accelerated so that it will be declared effective at 2:00 p.m.,
Eastern Time, on February 10, 2020, or as soon as practicable thereafter.

The Registrant respectfully
requests that it be notified of such effectiveness by a telephone call to Howard E. Berkenblit of Zysman, Aharoni, Gayer and Sullivan
& Worcester LLP at (617) 338-2979 and that such effectiveness also be confirmed in writing.

    Very truly yours,

    Oramed Pharmaceuticals Inc.

    By:
    /s/ Avraham Gabay

    Name:
    Avraham Gabay

    Title:
    Chief Financial Officer

SecProbe.io